Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 18/20 | 0.72 |
| ▸ | CA1 | P00915 | 18/20 | 0.72 |
| ▸ | CA2 | P00918 | 18/20 | 0.72 |
| ▸ | CA5A | P35218 | 18/20 | 0.72 |
| ▸ | CA9 | Q16790 | 18/20 | 0.72 |
| ▸ | CA5B | Q9Y2D0 | 18/20 | 0.72 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31187475 | 1.00 | CA12 (0.72) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL29635239 | 0.94 | CA12 (0.66) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL22294683 | 0.92 | CA12 (0.71) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL25892249 | 0.92 | CA12 (0.74) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL19456935 | 0.91 | CA12 (0.62) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL25854803 | 0.90 | CA12 (0.63) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL20888597 | 0.88 | CA12 (0.67) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL28937197 | 0.86 | CA12 (0.72) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL24767096 | 0.84 | CA12 (0.74) | CA12CA1CA2CA5ACA9 | |
| SCHEMBL30123365 | 0.84 | CA12 (1.00) | CA12CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2026-05-21 | — | — | US | disclosed |
| US-12527778-B2 | Enantiomers of a series of antiviral compounds | INNOVATIVE MOLECULES GMBH (DE) | 2026-01-20 | — | — | US | disclosed |
| US-12295945-B2 | Enantiomers of substituted thiazoles as antiviral compounds | INNOVATIVE MOLECULES GMBH (DE) | 2025-05-13 | — | — | US | disclosed |
| US-20240316021-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| CN-111433203-B | Enantiomer of substituted thiazoles as antiviral compounds | 创新分子股份有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4209491-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | Innovative Molecules GmbH (DE) | 2023-07-12 | — | — | EP | disclosed |
| EP-4209491-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | Innovative Molecules GmbH (DE) | 2023-07-12 | — | — | EP | disclosed |
| EP-3692039-B1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| EP-3692039-B1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| CN-109071473-B | Antiviral compounds | 创新分子股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-111433203-A | Enantiomers of substituted thiazoles as antiviral compounds | 创新分子股份有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20200148652-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH (DE) | 2020-05-14 | — | — | US | disclosed |
| US-20200148652-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH (DE) | 2020-05-14 | — | — | US | disclosed |
| US-10590094-B2 | Aminothiazole derivatives useful as antiviral agents | INNOVATIVE MOLECULES GMBH (DE) | 2020-03-17 | — | — | US | disclosed |
| US-10590094-B2 | Aminothiazole derivatives useful as antiviral agents | INNOVATIVE MOLECULES GMBH (DE) | 2020-03-17 | — | — | US | disclosed |
| US-20190112285-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20190112285-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2019068817-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019068817-A1 | ENANTIOMERS OF SUBSTITUTED THIAZOLES AS ANTIVIRAL COMPOUNDS | INNOVATIVE MOLECULES GMBH (DE) | 2019-04-11 | — | — | WO | disclosed |
| CN-109071473-A | Novel antivirus compound | 创新分子股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295945-B2 | Enantiomers of substituted thiazoles as antiviral compounds | EIF2AK2, MAVS, ZC3HAV1 | CA12 4867/4885CA1 4865/4885CA2 4604/4885 |
| US-20240316021-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, SARS1 | CA12 4748/4885CA1 4827/4885CA2 4611/4885 |
| US-20200148652-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | MAVS, EIF2AK2, SARS1 | CA12 4742/4885CA1 4843/4885CA2 4245/4885 |
| US-20190112285-A1 | Aminothiazole Derivatives Useful As Antiviral Agents | MAVS, EIF2AK2, SARS1 | CA12 4770/4885CA1 4844/4885CA2 4253/4885 |
| US-12527778-B2 | Enantiomers of a series of antiviral compounds | CA2, CA6, HCFC1 | CA12 4/4885CA1 6/4885CA2 1/4885 |
| US-20260137669-A1 | NOVEL ENANTIOMERS OF A SERIES OF ANTIVIRAL COMPOUNDS | IFNAR1, CCR10, EIF2AK2 | CA12 2877/4885CA1 4619/4885CA2 3814/4885 |
| US-10590094-B2 | Aminothiazole derivatives useful as antiviral agents | MAVS, EIF2AK2, SARS1 | CA12 4770/4885CA1 4844/4885CA2 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.